CRISPR Therapeutics AG — Director's Dealing 2021

Dec 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-12-02

Reporting Person: KASINGER JAMES R. (General Counsel and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-02	Common Shares	M	7342	$13.62	Acquired	36512	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-02	Stock Option (Right to Buy)	$13.62	M	7342	Disposed	2027-05-31	Common Shares (7342)	Direct

Footnotes

F1: This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% vested on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.